Investment Thesis
SI-BONE demonstrates strong revenue growth (20.2% YoY) and exceptional gross margins (79.8%), indicating a viable medical device product with market traction. However, persistent negative operating cash flow (-2.4M) and operating losses (-5.1M) despite robust top-line growth raise concerns about cost structure and path to profitability, warranting a cautious stance pending operational improvements.
Strengths
- Strong 20.2% YoY revenue growth with industry-leading 79.8% gross margins indicates robust product-market fit and pricing power
- Fortress balance sheet with 33.5M cash, low 0.20x debt/equity leverage, and 178.9M stockholders' equity provides substantial runway and financial flexibility
- Exceptional liquidity position (9.99x current ratio, 8.34x quick ratio) enables continued operations and strategic investments
Risks
- Negative operating cash flow (-2.4M) and free cash flow (-3.4M) demonstrate ongoing cash burn despite revenue growth, threatening long-term viability if trend persists
- Operating margin of -9.7% and net margin of -8.2% reveal structural profitability challenges with inability to convert strong gross margins into operating income due to high expenses
- Negative operating income relative to debt load (interest coverage -5.8x) indicates operational earnings insufficient to service debt obligations
Key Metrics to Watch
- Operating cash flow trend and path to cash flow breakeven
- Operating expense ratio relative to revenue growth rate to assess operating leverage
- Operating income trajectory toward profitability and margin expansion
- Cash burn rate and runway adequacy given current 33.5M cash position
Financial Metrics
Revenue
52.6M
Net Income
-4.3M
EPS (Diluted)
$-0.10
Free Cash Flow
-3.4M
Total Assets
242.7M
Cash
33.5M
Profitability Ratios
Gross Margin
79.8%
Operating Margin
-9.7%
Net Margin
-8.2%
ROE
-2.4%
ROA
-1.8%
FCF Margin
-6.5%
Balance Sheet & Liquidity
Current Ratio
9.99x
Quick Ratio
8.34x
Debt/Equity
0.20x
Debt/Assets
26.3%
Interest Coverage
-5.78x
Long-term Debt
35.6M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-12T06:57:14.479385 |
Data as of: 2026-03-31 |
Powered by Claude AI